You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News items for the week of June 8, 2020.
Bio-Techne said pathologists now have access to its fully automated RNAscope technology, providing them with a new tool to evaluate disease biomarkers.
The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management.
Customer site shutdowns, particularly in the last several weeks of the quarter, negatively impacted sales by about 3 percent, the firm said.
The reimbursement contract provides about 9 million additional men access to the urine-based, genomic EPI test, Bio-Techne said.
The firm said that in fiscal Q2, its China businesses continued to achieve greater than 20 percent growth, but its European business growth was soft year over year.
The company said it anticipates that more than 60 million Medicare beneficiaries will be covered for the ExoDx Prostate IntelliScore (EPI) test on Dec. 1.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
The firm noted that in the quarter, the US Food and Drug Administration granted Breakthrough Device designation for its exosome-based liquid biopsy test.
The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.